The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to ...

对于某些非肥胖而口咽部阻塞明显的重度OSA患者，可以考虑在应用CPAP治疗1～2个月、夜间呼吸暂停及低氧已基本纠正情况下施行UPPP手术治疗。术前和术中应严密监测患者的情况，术后必须定期随访，如手术失败，应使用CPAP治疗 [4] 。

Try a single issue or save on a subscription Issues delivered straight to your door or device ...

Dec. 18, 2024 — People with breathing problems during sleep may have a larger hippocampus, the area of the brain responsible for memory and thinking, according to a new study. The study, which ...

Obstructive sleep apnea (OSA) is very common with 15% to 30% of men in the United States and 10% to 15% of women having the ...

The "Sleep Apnea Devices Market Forecast Report by Types, Therapeutic Devices, Diagnostic Devices, End User, Country and ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...